Scarica l'app Stockscreener
9.38
3.00%
-0.29
Precedente Chiudi:
$9.67
Aprire:
$9.68
Volume 24 ore:
228.74K
Relative Volume:
1.19
Capitalizzazione di mercato:
$456.18M
Reddito:
$62.02M
Utile/perdita netta:
$-45.65M
Rapporto P/E:
-10.20
EPS:
-0.92
Flusso di cassa netto:
$-9.60M
1 W Prestazione:
-10.41%
1M Prestazione:
-0.32%
6M Prestazione:
-7.22%
1 anno Prestazione:
-1.05%
Intervallo 1D:
$9.27
$9.68
Intervallo di 1 settimana:
$9.27
$10.46
Portata 52W:
$7.44
$10.90
Theravance Biopharma Inc Stock (TBPH) Company Profile
Nome
Theravance Biopharma Inc
Settore
Industria
Telefono
650-808-6000
Indirizzo
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Confronta TBPH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
9.38 | 456.18M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | Iniziato | BTIG Research | Buy |
| 2024-01-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-11-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-09-15 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-08-25 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-10-14 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | Iniziato | JP Morgan | Overweight |
| 2020-06-15 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-05-13 | Iniziato | Cowen | Outperform |
| 2020-01-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-06 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-29 | Ripresa | Piper Jaffray | Overweight |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-06-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-05-11 | Reiterato | Needham | Buy |
| 2016-12-21 | Iniziato | Needham | Buy |
| 2016-11-03 | Iniziato | Piper Jaffray | Overweight |
| 2016-10-12 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | Iniziato | Guggenheim | Buy |
| 2016-06-20 | Reiterato | Leerink Partners | Outperform |
| 2016-05-12 | Iniziato | Leerink Partners | Outperform |
| 2016-05-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
Mostra tutto
Theravance Biopharma Inc Borsa (TBPH) Ultime notizie
Theravance Bio (TBPH) Soars 8.3%: Is Further Upside Left in the Stock? - MSN
Theravance Biopharma (NASDAQ:TBPH) Hits New 12-Month High – Should You Buy? - Defense World
Theravance Biopharma (NASDAQ:TBPH) Trading Up 8.8%Still a Buy? - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Reaches New 12-Month HighHere's Why - MarketBeat
Theravance Biopharma stock hits 52-week high at $10.47 - MSN
Theravance biopharma SVP Rhonda Farnum sells $36,000 in shares - MSN
Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum Sells 4,000 Shares - MarketBeat
Theravance Biopharma stock hits 52-week high at $10.47 By Investing.com - Investing.com South Africa
Theravance Biopharma (NASDAQ:TBPH) shareholders are up 15% this past week, but still in the red over the last five years - Simply Wall St
Theravance biopharma SVP Rhonda Farnum sells $36,000 in shares By Investing.com - Investing.com UK
JPMorgan Chase & Co. Acquires 7,620 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Barclays PLC Increases Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Barclays PLC Has $529,000 Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
How To Trade (TBPH) - Stock Traders Daily
Zacks Research Issues Optimistic Estimate for TBPH Earnings - Defense World
Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Research Report 2024-2030 Featuring Allergan, Basilea Pharmaceutica, Merck, Pfizer, The Medicines Co, Theravance Biopharma - GlobeNewswire
Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs - GlobeNewswire
(TBPH) On The My Stocks Page - Stock Traders Daily
Analysts Are Optimistic We'll See A Profit From Theravance Biopharma, Inc. (NASDAQ:TBPH) - Yahoo Finance
Franklin Resources Inc. Trims Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Barclays PLC Has $529,000 Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Jane Street Group LLC Raises Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by State Street Corp - MarketBeat
State Street Corp Decreases Stock Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 21,372 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Wellington Management Group LLP Sells 159,258 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
When (TBPH) Moves Investors should Listen - Stock Traders Daily
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference - PR Newswire
Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue? - MSN
The past five years for Theravance Biopharma (NASDAQ:TBPH) investors has not been profitable - Yahoo Finance
Diabetic Gastroparesis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Theravance Biopharma, Eli Lilly and Company, Processa Pharmaceuticals, PTC Therapeutics - The Globe and Mail
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
What is Zacks Research's Estimate for TBPH FY2024 Earnings? - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Acquired by BNP Paribas Financial Markets - MarketBeat
(TBPH) Trading Advice - Stock Traders Daily
Theravance Biopharma (STU:0TB) Shares Outstanding (EOP) : 49.17 Mil (As of Sep. 2024) - GuruFocus.com
105,609 Shares in Theravance Biopharma, Inc. (NASDAQ:TBPH) Bought by Algert Global LLC - MarketBeat
Trading (TBPH) With Integrated Risk Controls - Stock Traders Daily
Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
Multiple System Atrophy Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma - The Globe and Mail
Theravance Biopharma to Participate in an Upcoming Investor Conference - Citizentribune
Theravance Biopharma to Present at Evercore HealthCONx Conference | TBPH Stock News - StockTitan
Baupost's top Q3 trades include Jazz exit, new Dollar General stake - MSN
Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates - MSN
(TBPH) Investment Report - Stock Traders Daily
Theravance Biopharma Inc (TBPH) Quarterly 10-Q Report - Quartzy
Madison Avenue Partners, LP Expands Stake in Theravance Biopharm - GuruFocus.com
Theravance Biopharma Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Theravance Biopharma Inc Azioni (TBPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):